Ledraxen (Enoxaparin Sodium)

Enoxaparin sodium enhances the activity of antithrombin III, which selectively inhibits factor Xa and, to a lesser extent, thrombin (factor IIa). This reduces the generation of thrombin and the formation of fibrin clots, delivering anticoagulant protection while preserving some clotting ability.

The dose of Ledraxen is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and procedural context. Dosing regimens are detailed in the product label and should be followed exactly as directed by a qualified healthcare professional.

Safety data for enoxaparin in pregnancy are limited, and the drug should only be used when the potential maternal benefit justifies any possible fetal risk. Breastfeeding considerations are similar; the decision should be made by the prescriber after evaluating the risk‑benefit profile for both mother and infant.

To place an order, submit an enquiry on the Ledraxen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Compared with unfractionated heparin, enoxaparin (Ledraxen) has more predictable pharmacokinetics, a longer half‑life, and does not require routine laboratory monitoring in most patients. It offers a lower risk of heparin‑induced thrombocytopenia and can be administered subcutaneously, whereas unfractionated heparin is typically given intravenously and needs frequent aPTT monitoring.

Ledraxen should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Once removed from refrigeration, it may be kept at controlled room temperature for a limited period as indicated in the product label, but re‑refrigeration is recommended if use is delayed.

Ledraxen is administered by subcutaneous injection, intravenous infusion, or through the haemodialysis circuit, depending on the clinical indication. Injection sites are typically the abdomen or thigh, and the technique should follow aseptic guidelines. Intravenous dosing is performed under controlled conditions in a healthcare setting.

The most serious risks include major bleeding events such as intracranial or gastrointestinal hemorrhage, heparin‑induced thrombocytopenia (HIT), spinal or epidural hematoma, and severe allergic reactions. Patients should be monitored for signs of unexpected bleeding, sudden drops in platelet count, or neurologic changes.

Ledraxen is contraindicated in patients with active major bleeding, known hypersensitivity to enoxaparin or any component of the formulation, and those with a history of heparin‑induced thrombocytopenia. Caution is also advised for individuals with severe renal impairment, uncontrolled hypertension, or recent intracranial surgery.